current on stereotactic body radiation therapy for pancreatic cancer.
暂无分享,去创建一个
[1] David Goldstein,et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.
[2] Daniel T Chang,et al. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT , 2016, American journal of clinical oncology.
[3] T. Strom,et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma , 2015, Acta oncologica.
[4] J. Cameron,et al. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience , 2015, Annals of Surgical Oncology.
[5] Albert C. Koong,et al. Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma , 2014, Cancer.
[6] A. Koong,et al. Stereotactic body radiation therapy in pancreatic cancer: the new frontier , 2014, Expert review of anticancer therapy.
[7] Jeffrey W. Clark,et al. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. , 2014, International journal of radiation oncology, biology, physics.
[8] T. Pawlik,et al. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. , 2014, International journal of radiation oncology, biology, physics.
[9] Donghui Li,et al. Biomarkers of TGF-β Signaling Pathway and Prognosis of Pancreatic Cancer , 2014, PloS one.
[10] A. Krasinskas,et al. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer , 2013, Radiation oncology.
[11] M. Scorsetti,et al. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience , 2013, Radiation oncology.
[12] E. Mok,et al. Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer. , 2013, International journal of radiation oncology, biology, physics.
[13] J. Marshall,et al. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety , 2013, Radiation oncology.
[14] D. Heron,et al. Adjuvant Stereotactic Body Radiotherapy for Resected Pancreatic Adenocarcinoma with Close or Positive Margins , 2012, Journal of Gastrointestinal Cancer.
[15] R. Timmerman,et al. The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology , 2011, Clinical & developmental immunology.
[16] M. Scorsetti,et al. Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments , 2011, Radiation oncology.
[17] T. Desser,et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.
[18] K. Lillemoe,et al. A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation , 2011, Annals of surgery.
[19] Gang Li,et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. , 2011, Surgery.
[20] H. Friess,et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.
[21] A. Koong,et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. , 2010, International journal of radiation oncology, biology, physics.
[22] Paolo Francescon,et al. Unresectable Locally Advanced Pancreatic Cancer: A Multimodal Treatment Using Neoadjuvant Chemoradiotherapy (Gemcitabine Plus Stereotactic Radiosurgery) and Subsequent Surgical Exploration , 2010, Annals of Surgical Oncology.
[23] J. Norton,et al. Interfractional uncertainty in the treatment of pancreatic cancer with radiation. , 2010, International journal of radiation oncology, biology, physics.
[24] Alison P. Klein,et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Lockwood,et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] T. Desser,et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. , 2008, International journal of radiation oncology, biology, physics.
[27] E. Jaffee,et al. Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation , 2008, Clinical Cancer Research.
[28] E. Touboul,et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Quynh-Thu Le,et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. , 2005, International journal of radiation oncology, biology, physics.
[30] H. von der Maase,et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[31] Jeffrey W. Clark,et al. Long-term Results of Intraoperative Electron Beam Irradiation (IOERT) for Patients With Unresectable Pancreatic Cancer , 2005, Annals of surgery.
[32] Albert C Koong,et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. , 2004, International journal of radiation oncology, biology, physics.
[33] Joel G Fletcher,et al. Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT. , 2003, Radiology.
[34] S. Ellenberg,et al. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. , 1985, Archives of surgery.
[35] The University of Maryland , 1883, The American journal of dental science.
[36] A. Jemal,et al. Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[37] E. Diamandis,et al. Pancreatic cancer. , 2013, Clinical chemistry.
[38] M. Mino‐Kenudson,et al. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. , 2011, International journal of radiation oncology, biology, physics.
[39] T. Eberlein. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial , 2008 .
[40] N. Dubrawsky. Cancer statistics , 2022 .